Ilika secures first commercial Stereax electrode order from Cirtec Medical

Ilika

Ilika plc (LON:IKA), the UK pioneer in solid state battery technology, has secured its first revenue-generating purchase order from Cirtec Medical for the supply of Stereax electrodes, marking the commercial transition of this strategic partnership. This milestone order for the critical conductive elements that enable battery functionality follows two years of development work and successful prototype delivery in December 2025.

The Stereax electrodes will support the ramp up of Stereax M300 production at Cirtec, targeting a wide range of applications across active implantable medical devices (AIMDs), including powering implanted sensors, neurostimulators, orthopaedic implants, orthodontic wearables and ophthalmology devices. This purchase represents Ilika’s entry into the commercial phase of its medical device battery technology.

In August 2023, Ilika announced an agreement whereby the Company would retain specific battery manufacturing processes at its UK facility as a service to Cirtec. After successfully delivering early versions of Stereax M300 batteries in December 2025 (with primary manufacturing occurring at Cirtec’s Massachusetts facility), this relationship has now progressed to commercial orders, with Cirtec purchasing production quantities of electrodes from Ilika. The Stereax M300 batteries are currently being evaluated by 21 customers for their applications.

Shawn Martin, Vice President at Cirtec Medical, said: “This marks an important transition from the earlier stages of technology transfer to commercial production coordinated from our facility here in the USA.”

Graeme Purdy, CEO of Ilika, said: “The receipt of this first commercial electrode order validates the strong market momentum building behind our Stereax technology and demonstrates the successful execution of our production strategy. This revenue-generating phase of our partnership with Cirtec positions us to support their manufacturing scale-up while accelerating product integration across numerous high-value medical device applications.”

The companies will showcase their partnership at upcoming industry events, with Ilika supporting Cirtec at the North America Neuromodulation Society (NANS) annual meeting in Las Vegas on January 23-24, 2026. Additionally, Cirtec will exhibit and represent Stereax technology at MD&M West in Anaheim on February 3-5, 2026, further highlighting the commercial readiness of this innovative battery solution.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Ilika Stereax batteries to feature at MEDevice Silicon Valley

Ilika will have its Stereax technology represented by Cirtec Medical at MEDevice Silicon Valley on 18 and 19 November 2026, providing further exposure to its medical device battery technology.

Ilika targets Europe’s next phase of solid-state battery development

Ilika is positioned around Europe’s push for next-generation solid-state batteries as manufacturers seek better performance and less dependence on Asian supply chains.

Ilika targets lighter EV battery packs

Ilika’s Goliath solid-state battery technology targets a higher cell-to-pack ratio by combining high-nickel NMC chemistry with a non-flammable solid electrolyte.

Ilika’s Graeme Purdy on Goliath, defence and Brompton progress (LON:IKA)

Ilika CEO Graeme Purdy discusses the completion of the PRIMED programme, improved consistency in Goliath battery performance, growing defence interest and progress with Brompton on e-bike battery applications.

Ilika appoints Robin Anderton-Brown as strategic defence advisor

Former UK Strategic Command Director of Capability Robin Anderton-Brown joins Ilika as a strategic advisor, supporting opportunities for its Goliath solid-state batteries in the defence sector.

Search